Evodenoson

SKU: orb1697251

Description

Evodenoson (ATL313) is a selective adenosine A2a receptor agonist used in research for ocular diseases, oncology, and immunology. Its applications include studies in models of glaucoma and hematologic tumors, supported by both in vitro and in vivo experimental data.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 844873-47-8
• MW: 499.52
• Purity: 99.84%
• Formula: C₂₃H₂₉N₇O₆
• SMILES: O[C@H]1[C@H](N2C=3C(N=C2)=C(N)N=C(C#CCC4CCN(C(OC)=O)CC4)N3)O[C@H](C(NC5CC5)=O)[C@H]1O
• Target: Adenosine Receptor
• Solubility: DMSO:50 mg/mL (100.1 mM)

Bioactivity

• In Vivo:
  The rats were divided into 3 groups: Group 1 received a continuous intravenous infusion of saline given 10 min prior to ischemia and throughout reperfusion (n=8); Group 2 received a continuous intravenous infusion of 10 ng/kg/min of ATL 313 given 10 min prior to ischemia and throughout reperfusion (n=8); and group 3 received an intravenous bolus of ATL 313 (900 ng/Kg body weight) given 10 min prior to ischemia, and continuous intravenous infusion of 10 ng/kg/min of ATL 313 started at 20 min after ischemia and throughout reperfusion (n=8). After the euthanasia of the rats, the hearts were harvested for the assessment of the risk zone and zone of necrosis of the left ventricle. Conclusion: A(2A)AR agonist ATL 313 significantly reduced infarct size and improved LV contractility at the end of reperfusion assessed by LV dp/dt at a dose of 900 ng/Kg. The mechanisms for the observed cardioprotection effect of ATL 313 remain to be determined.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AdenosineReceptor, Adenosine Receptor, A2A, ATL 313, ATL313, ATL-313, Evodenoson, DE 112, DE112, DE-112

Compound Identifiers

PubChem CID

11627443